Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
About Us
Conferences
Videos
Webinars
Media & Press
Top Story
Product Launch
C2N Diagnostics launching next-generation blood test for Alzheimer's disease detection
With an anticipated launch in the first quarter of 2023, the PrecivityAD2 blood test would facilitate earlier diagnosis of Alzheimer's disease pathology than is possible with current tests, the firm said.
Featured
Infectious
Dr. Fauci invokes Yogi Berra to describe emerging infectious disease challenge
Heart Disease
‘Good’ cholesterol worse for some adults: NIH study
Latest News
MDxHealth sees Medicare delay for prostate cancer risk test, expects lower 2022 revenue
November 30, 2022
Aspira announces commercial launch of blood-based ovarian cancer risk assay
November 30, 2022
Myriad Genetics to present new data at San Antonio Breast Cancer Symposium
November 30, 2022
PreciseDx, Dordrecht Albert Schweitzer Hospital to evaluate cancer risk stratification platform
November 29, 2022
Business Insights
Collaboration
Biora Therapeutics, Avero Diagnostics to develop preeclampsia rule-out test
COVID-19
KSL Pulse Scientific to distribute Lucira Health COVID, flu molecular test in Canada
Molecular Diagnostics
Sherlock Biosciences secures funding to further develop CRISPR testing platform
CLIA
Chembio Diagnostics applies for FDA CLIA waiver for HIV, syphilis test
Diagnostic Technologies
Molecular Diagnostics
Myriad Genetics to present new data at San Antonio Breast Cancer Symposium
Artificial Intelligence
PreciseDx, Dordrecht Albert Schweitzer Hospital to evaluate cancer risk stratification platform
Molecular Diagnostics
Sherlock Biosciences secures funding to further develop CRISPR testing platform
Point-of-Care Testing
Sonic Healthcare investing $17.8M to acquire 19.99% of Microba Life Sciences
Diseases
Payor Coverage
MDxHealth sees Medicare delay for prostate cancer risk test, expects lower 2022 revenue
Product Launch
C2N Diagnostics launching next-generation blood test for Alzheimer's disease detection
Collaboration
Biora Therapeutics, Avero Diagnostics to develop preeclampsia rule-out test
COVID-19
KSL Pulse Scientific to distribute Lucira Health COVID, flu molecular test in Canada
More from LabPulse.com
Biora Therapeutics, Avero Diagnostics to develop preeclampsia rule-out test
Under the terms of an agreement, Biora would receive milestone payments and royalties on net sales if the test reaches the market.
November 29, 2022
KSL Pulse Scientific to distribute Lucira Health COVID, flu molecular test in Canada
The test was approved by Health Canada and will be available to healthcare providers and consumers for the fall and winter COVID and flu season.
November 29, 2022
Sherlock Biosciences secures funding to further develop CRISPR testing platform
The company said it will use the funding to further develop its CRISPR testing platform, enabling broader testing in low- and middle-income countries.
November 29, 2022
Thermo Fisher Scientific introduces digital PCR liquid-biopsy assays for academic, clinical research
The assays are predesigned for research to identify genetic mutations, including challenging cancer hotspot mutations, and to help enable simplification of liquid biopsy workflows, Thermo Fisher said.
November 29, 2022
Sonic Healthcare investing $17.8M to acquire 19.99% of Microba Life Sciences
The firms have also agreed on initial terms for a strategic partnership to distribute Microba's microbiome testing technology in Australia, Germany, U.K., Switzerland, U.S., New Zealand, and Belgium.
November 29, 2022
Fors Marsh to offer Sera Prognostics preterm birth risk test to employees
The PreTRM blood-based test provides early risk assessment for spontaneous preterm birth in asymptomatic, singleton pregnancies.
November 29, 2022
Most Popular
DNA forensic evidence frees Ohio man of rape, attempted rape
Chembio Diagnostics applies for FDA CLIA waiver for HIV, syphilis test
Dr. Fauci invokes Yogi Berra to describe emerging infectious disease challenge
AnchorDx enrolling U.S. clinical trial for bladder cancer assay
Thermo Fisher Scientific updates Applied Biosystems genetic analyzers to comply with IVDR
Week in Review: Elizabeth Holmes sentenced; good cholesterol worse for some adults; earlier type 2 diabetes diagnosis; and more
More from LabPulse.com
Chembio Diagnostics applies for FDA CLIA waiver for HIV, syphilis test
Using a small blood sample, the test detects antibodies for HIV types 1 and 2 as well as Treponema pallidum, the bacteria that causes syphilis.
November 28, 2022
Blood-based MDx test developer DiamiR to present poster on trial findings at CTAD
The poster will be presented during the session “Clinical trials: Biomarkers including plasma” during the 15th Clinical Trials on Alzheimer’s Disease (CTAD) in San Francisco from November 29 to December 2.
November 28, 2022
Halo Diagnostics, Ikonopedia partner to integrate genetic testing, breast cancer imaging software
Halo Diagnostics announced a partnership with Ikonopedia that aims to improve the detection of breast cancer by integrating genetic testing with imaging.
November 28, 2022
Thermo Fisher Scientific updates Applied Biosystems genetic analyzers to comply with IVDR
IVDR-compliant versions of both analyzers and corresponding consumables are now available in the majority of EU territories.
November 28, 2022
Quest Diagnostics completes acquisition of Summa Health outreach lab services business
Quest said that as a result of the acquisition, physicians and patients in northeastern Ohio will gain access to its test menu and broad health plan relationships.
November 28, 2022
Low-value prostate cancer screening has Medicare spending ramifications, study finds
The consequences of low-value PSA cancer screening could amount to more than $275 million in spending for Medicare, according to the authors' estimates.
November 22, 2022
